Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus

Abstract

ObjectivesTo investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE).MethodsThe study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm3 at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm3. The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated.ResultsOf 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%).ConclusionsThrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.

Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population

“…19 The age of the thrombocytopaenia group was higher than that of the non-thrombocytopaenia group, which was different from previous studies. 19 Jiang et al. 19 found no significant differences in age between the thrombocytopaenia group and non-thrombocytopaenia group.…”

“…19 Jiang et al. 19 found no significant differences in age between the thrombocytopaenia group and non-thrombocytopaenia group. This result may be due to the fact that SLE patients included in this study were all inpatient patients, while patients in the CSTAR registry may have included patients in the outpatient department.…”

“…18 The prevalence of thrombocytopaenia diagnosed in SLE patients in our study was higher than in the recently published findings based on the Chinese SLE Treatment and Research group (CSTAR) registry. 19 Jiang et al.’s study included 2104 SLE patients and found a diagnosis rate of 16.3% in SLE patients with thrombocytopaenia. 19 The age of the thrombocytopaenia group was higher than that of the non-thrombocytopaenia group, which was different from previous studies.…”

“…19 Jiang et al.’s study included 2104 SLE patients and found a diagnosis rate of 16.3% in SLE patients with thrombocytopaenia. 19 The age of the thrombocytopaenia group was higher than that of the non-thrombocytopaenia group, which was different from previous studies. 19 Jiang et al.…”

“…32 We found that hypocomplementaemia and leucopaenia were independent risk factors for thrombocytopaenia, which were consistent with previous studies and clinical experience. 19,32…”